Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

Phase 2 Completed 200 enrolled University Hospital Muenster Bayer · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).

Timeline

Start: 2006-09
Primary completion: 2009-07
Completion: 2009-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Sorafenib	Small molecule	400 mg	—

Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

Summary

Timeline

Drugs

Indications